Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
Item | Description | The company |
---|---|---|
EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Edwards Lifesciences Corp. EBITDA decreased from 2019 to 2020 but then increased from 2020 to 2021 exceeding 2019 level. |
Enterprise Value to EBITDA Ratio, Current
Selected Financial Data (US$ in thousands) | |
Enterprise value (EV) | 66,267,039) |
Earnings before interest, tax, depreciation and amortization (EBITDA) | 1,855,200) |
Valuation Ratio | |
EV/EBITDA | 35.72 |
Benchmarks | |
EV/EBITDA, Competitors1 | |
Abbott Laboratories | 19.79 |
Cigna Group | 11.27 |
CVS Health Corp. | 6.70 |
Elevance Health Inc. | 7.72 |
Humana Inc. | 5.53 |
Intuitive Surgical Inc. | 78.91 |
Medtronic PLC | 15.25 |
UnitedHealth Group Inc. | 16.17 |
EV/EBITDA, Sector | |
Health Care Equipment & Services | 15.68 |
EV/EBITDA, Industry | |
Health Care | 14.72 |
Based on: 10-K (reporting date: 2021-12-31).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Enterprise value (EV)1 | 66,267,037) | 53,931,479) | 47,290,710) | 36,573,998) | 27,806,373) | |
Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 1,855,200) | 1,039,700) | 1,276,500) | 868,700) | 1,140,000) | |
Valuation Ratio | ||||||
EV/EBITDA3 | 35.72 | 51.87 | 37.05 | 42.10 | 24.39 | |
Benchmarks | ||||||
EV/EBITDA, Competitors4 | ||||||
Abbott Laboratories | 17.42 | 25.99 | 21.70 | — | — | |
Cigna Group | 9.06 | 6.31 | 8.42 | — | — | |
CVS Health Corp. | 10.41 | 8.56 | 9.43 | — | — | |
Elevance Health Inc. | 10.05 | 7.57 | 9.05 | — | — | |
Humana Inc. | 11.22 | 6.91 | 9.30 | — | — | |
Intuitive Surgical Inc. | 44.54 | 59.12 | 37.53 | — | — | |
Medtronic PLC | 24.41 | 17.92 | 16.01 | — | — | |
UnitedHealth Group Inc. | 17.39 | 13.39 | 13.82 | — | — | |
EV/EBITDA, Sector | ||||||
Health Care Equipment & Services | 15.20 | 12.74 | 12.95 | — | — | |
EV/EBITDA, Industry | ||||||
Health Care | 13.31 | 16.61 | 14.16 | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
3 2021 Calculation
EV/EBITDA = EV ÷ EBITDA
= 66,267,037 ÷ 1,855,200 = 35.72
4 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
EV/EBITDA | Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. | Edwards Lifesciences Corp. EV/EBITDA ratio increased from 2019 to 2020 but then decreased significantly from 2020 to 2021. |